China-based drug maker Henlius has announced that the European Medicines Agency (EMA) has accepted for review the company’s marketing authorization application for a trastuzumab biosimilar, HLX02, referencing Herceptin.
China-based drug maker Henlius has announced that the European Medicines Agency (EMA) has accepted for review the company’s marketing authorization application (MMA) for a trastuzumab biosimilar, HLX02, referencing Herceptin.
"We are very pleased to receive the EMA acceptance to review of our trastuzumab biosimilar HLX02 MAA submission," Scott Liu, PhD, cofounder, president, and chief executive officer at Henlius, said in a statement announcing the application. "It shows that our clinical, medical, regulatory affairs and quality system capabilities have been internationally recognized. We plan to work closely with EMA on this HLX02 MAA and hope to benefit [HER2-positive] cancer patients globally with its high quality and affordability."
Last year, during the European Society for Medical Oncology’s 2018 annual meeting, Henlius reported on the clinical program for the biosimilar.1 The drug maker indicated that it had enrolled 12 healthy male volunteers to evaluate the safety and tolerability of a single infusion of the biosimilar at 2, 4, 6, and 8 mg/kg. The different concentrations demonstrated acute and dose-dependent effects on serum concentration.
A subsequent demonstration of safety and pharmacokinetic equivalence of the biosimilar and its US- and EU-licensed reference products was conducted in 109 healthy male volunteers. No deaths, serious adverse events, or antidrug antibodies were observed in any of the groups.
Finally, a phase 3 study was conducted in 649 patients with previously untreated HER2-positive metastatic breast cancer at centers in China, Ukraine, Poland, and the Philippines.
Henlius’ biosimilar trastuzumab is also under review by authorities at the National Medical Products Administration in China, which recently approved another Henlius biosimilar, HLX01, a rituximab product.
If approved, HLX02 would join a growing number of biosimilar options referencing Herceptin: Currently approved in the European Union are Trazimera, Ogivri, Ontruzant, Herzuma, and Kanjinti.
Reference
1. Zhang Q, Xu B, Zhang Q, et al. Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar. Presented at: European Society for Medical Oncology Asia 2018 Congress; November 23-25, 2018; Singapore. Abstract 44P.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.